Corpus Intelligence IC Memo — STEWARD CARNEY HOSPITAL INC 2026-04-26 09:07 UTC
IC Memo — STEWARD CARNEY HOSPITAL INC
Investment Committee Memorandum | MA | 106 beds | Grade D | EBITDA uplift $6.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STEWARD CARNEY HOSPITAL INC

CCN 220017 | SUFFOLK, MA | 106 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

STEWARD CARNEY HOSPITAL INC is a 106-bed safety-net/medicaid heavy in SUFFOLK, MA with $92.2M in net patient revenue and a -46.6% operating margin. The hospital serves a payer mix of 19.5% Medicare, 33.4% Medicaid, and 47.1% commercial.

Thesis: Undervalued. Our ML models identify $6.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -46.6% to -39.2% (+736bps).

Net Revenue HCRIS$92.2M
Current EBITDA COMPUTED$-43.0M
Operating Margin COMPUTED-46.6%
Occupancy HCRIS51.2%
Revenue / Bed COMPUTED$870K
Net-to-Gross HCRIS53.6%
Distress Probability ML57.9%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
56
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -46.6% places it below the state median. Among 56 size-comparable peers (53-212 beds), the median margin is -9.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (53-212), prioritizing same-state peers. 56 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STEWARD CARNEY HOSPITAL INC (Target)MA106$92.2M-46.6%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
MOUNT AUBURN HOSPITALMA186$337.4M-8.4%
STEWARD ST. ANNES HOSPITALMA175$322.3M12.8%
FAULKNER HOSPITALMA147$316.6M-7.9%
EMERSON HOSPITALMA111$315.1M-10.1%
WINCHESTER HOSPITALMA178$314.9M-3.9%
BROCKTON HOSPITAL INC.MA175$305.2M-18.4%
GOOD SAMARITAN MEDICAL CENTERMA208$300.2M7.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.9M+210bp18mo
Cost to Collect4.5%2.5%$1.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.1M+122bp9mo
Clean Claim Rate88.0%96.0%$59K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.9M
Cost to Collect
$1.8M
Denial Rate Reduction
$1.8M
A/R Days Reduction
$1.1M
Clean Claim Rate
$59K
Total EBITDA Uplift$6.8M
Current EBITDA$-43.0M
+ RCM Uplift+$6.8M
Pro Forma EBITDA$-36.2M
Current Margin-46.6%
Pro Forma Margin-39.2%
WC Released (1x)$3.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-66.1M$-215.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-66.1M$-258.5M0.00x-100.0%
Bull Case9.0x11.0x$-59.5M$-257.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-59.5M$-298.6M0.00x-100.0%
Bear Case11.0x10.0x$-72.7M$-228.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-72.7M$-274.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (33.4%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 57.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 56 hospitals with 53-212 beds
  • Same-state prioritization (n=57)
  • Comp margins: P25=-17.6% / P50=-9.3% / P75=2.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.